LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Lista de Ações・Denali Therapeutics Inc

Denali Therapeutics Inc

Fechado

SetorSaúde

19.28 2.17

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

18.14

Máximo

19.3

Indicadores-chave
By Trading Economics
Rendimento	102K -128M
EPS	-0.69
Funcionários	507
EBITDA	-9.8M -135M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+98.29% upside

Dividendos
By Dow Jones
Próximos Ganhos	7 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-42M 2.9B
Abertura anterior	17.11
Fecho anterior	19.28

Sentimento de Notícias

By Acuity

50%

159 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

13.355 / 16.44 Suporte e Resistência

Denali Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

20 de mai. de 2026, 23:31 UTC

Ações em Alta

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 de mai. de 2026, 22:52 UTC

Grandes Movimentos do Mercado

Osisko Shares Fall on Planned Convertible Notes Offering

20 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 de mai. de 2026, 23:44 UTC

Ganhos

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 de mai. de 2026, 23:35 UTC

Conversa de Mercado

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de mai. de 2026, 23:17 UTC

Conversa de Mercado

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 de mai. de 2026, 23:15 UTC

Conversa de Mercado

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 de mai. de 2026, 23:14 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 de mai. de 2026, 23:02 UTC

Conversa de Mercado

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

20 de mai. de 2026, 22:57 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

20 de mai. de 2026, 22:51 UTC

Conversa de Mercado

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 de mai. de 2026, 22:51 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 de mai. de 2026, 22:27 UTC

Conversa de Mercado

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 de mai. de 2026, 22:14 UTC

Conversa de Mercado

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 de mai. de 2026, 22:10 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 de mai. de 2026, 22:00 UTC

Ganhos

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 de mai. de 2026, 21:38 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 de mai. de 2026, 21:27 UTC

Ganhos

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 de mai. de 2026, 21:20 UTC

Ganhos

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 de mai. de 2026, 21:19 UTC

Ganhos

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 de mai. de 2026, 21:18 UTC

Ganhos

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 de mai. de 2026, 21:17 UTC

Ganhos

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 de mai. de 2026, 21:16 UTC

Ganhos

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparação entre Pares

Variação de preço

Denali Therapeutics Inc Previsão

Preço-alvo

By TipRanks

98.29% parte superior

Previsão para 12 meses

Média 35.91 USD 98.29%

Máximo 42 USD

Mínimo 23 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

13.355 / 16.44Suporte e Resistência

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentimento

By Acuity

159 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.